Products for Research Use Only

Olodaterol

CAT: 0804-HY-14301-01Size: 2 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14301-01Size:2 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Olodaterol (BI1744) is a selective, long acting β2-adrenoceptor (β2-AR) agonist (EC50=0.1 nM and pKi= 9.14 for human β2-adrenoceptor, respectively) . Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis[1][2][3].
CAS Number
868049-49-4
Product Name Alternative
BI1744
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Adrenergic Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Endocrinology
Assay Protocol
https://www.medchemexpress.com/Olodaterol.html
Purity
99.85
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic; warming)
Smiles
O=C1NC2=CC(O)=CC([C@@H](O)CNC(C)(C)CC3=CC=C(OC)C=C3)=C2OC1
Molecular Formula
C21H26N2O5
Molecular Weight
386.44
Precautions
H302, H315, H319, H335
References & Citations
[1]Xing G, et al. Design, synthesis and biological evaluation of 8- (2-amino-1-hydroxyethyl) -6-hydroxy-1,4-benzoxazine-3 (4H) -one derivatives as potent β2-adrenoceptor agonists. Bioorg Med Chem. 2020;28 (1) :115178.|[2]Herrmann FE, et al. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis. Br J Pharmacol. 2017;174 (21) :3848-3864.|[3]Bouyssou T, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models [published correction appears in J Pharmacol Exp Ther. 2013 Jul;346 (1) :161]. J Pharmacol Exp Ther. 2010;334 (1) :53-62.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
β adrenergic receptor

Popular Products